Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (443 reviews)

For research use only.

Catalog No.S1025 Synonyms: Iressa

443 publications

CAS No. 184475-35-2

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Selleck's Gefitinib (ZD1839) has been cited by 443 publications

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )
Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Elife, 2020, 9e60541

PubMed: 32940599 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01465-y

PubMed: 32978523 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):768

PubMed: 32943616 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )
J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):87

PubMed: 33012785 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Invest New Drugs, 2020, 38(4):1003-1011

PubMed: 31612426 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13670

PubMed: 32956565 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )
Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020,

PubMed: 32843430 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Cancer Treat Res Commun, 2020, 25:100229

PubMed: 33152554 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )
J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Mol Cancer, 2019,

PubMed: 31747941 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Cell Prolif, 2019,

PubMed: 31094020 ( click the link to review the publication )
Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Mol Carcinog, 2019,

PubMed: 30811684 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Mediators Inflamm, 2019,

PubMed: 32082070 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )
J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Mol Med Rep, 2019,

PubMed: 31638204 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30975694 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )
Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

EMBO Rep, 2018,

PubMed: 29335246 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018,

PubMed: 29961070 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )
Mol Oncol, 2018, 12(6):883-895

PubMed: 29633504 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):1775-1786

PubMed: 29624806 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Sci, 2018,

PubMed: 29487179 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )
Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Gen Virol, 2018,

PubMed: 29624161 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1311-1320

PubMed: 29907991 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Neuro-oncology, 2017,

PubMed: 28575494 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )
Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Oncogene, 2017, 36(6):731-745

PubMed: 27477696 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

ACS Infect Dis, 2017, 3(8):564-574

PubMed: 28537707 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28684780 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28939861 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017,

PubMed: 28927099 ( click the link to review the publication )
Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(40):69185-69197

PubMed: 28978189 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28427242 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26640141 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )
Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Anal Biochem, 2016,

PubMed: 27059751 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50258-50276

PubMed: 27384680 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Tumour Biol, 2016,

PubMed: 26286833 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27556697 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )
Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

EMBO Rep, 2015,

PubMed: 26341626 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2947-58

PubMed: 26089022 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25746002 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26469972 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26268703 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26639561 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )
Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Mol Med Rep, 2015,

PubMed: 25483995 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23857-73

PubMed: 26160843 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Int J Biol Sci, 2014,

PubMed: 25013379 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Prostate, 2014, 74(5):528-36

PubMed: 24435707 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):2230-6

PubMed: 25175149 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115144

PubMed: 25502225 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )
PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277177 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )
Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62852

PubMed: 23696788 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 2):435-48

PubMed: 22357970 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )
PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	M4rGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwMEW0JO69VQ>?	M3n1XVE3PTF4NEez
NIH3T3	MVXGeY5kfGmxbjDBd5NigQ>?	MVuwMlIh\|ryP	MljWNkBp	NFvpeVBFVVOR	MWPJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>	NX3qS4FzOTZ2OECyPFQ>
COS7	NYnmeINjTnWwY4Tpc44hSXO\|YYm=	MlPHPVYh\|ryP			NUTpcFZjUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{\WR?	NITmV2QyPzF5OEeyNi=>
A549	M4fPO2N6fG:2b4jpZ{BCe3OjeR?=		NVfZfmhFQTZiaB?=	M3z1ZmROW09?	NWDQV2NkUUN3ME2xN{42QSEQvF2=	Ml7SNVg{OTN6MEe=
K562	NV\uT\|ZqS3m2b4TvfIlkKEG\|c3H5		MVm5OkBp	MXvEUXNQ	M4TKZWlEPTB;OT6zOkDPxE1?	NWL1cHh7OTh\|MUO4NFc>
MDA-MB-231	NEjHSolEgXSxdH;4bYMhSXO\|YYm=		MYW5OkBp	MYfEUXNQ	NHTpTGlKSzVyPUO2MlYyKM7:TR?=	NVHB[GtbOTh\|MUO4NFc>
MOLT4	MWTDfZRwfG:6aXOgRZN{[Xl?		M33NXVk3KGh?	M4LsNGROW09?	NELCWIVKSzVyPUG1MlAzKM7:TR?=	MWmxPFMyOzhyNx?=
MCF7	MorKR5l1d3SxeHnjJGF{e2G7	M3PreVUxKM7:TR?=	MWG3NkBp		NHzQZotKSzVyPUGyMlA2KM7:TR?=	M{KxN\|E5PzdzOEG5
BT474	M3fFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmizO\|IhcA>?		M3n4bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgc5ZmemW6cILld5NqdmdiRWLCZlIhf2m2aDDFR\|UxKG:oIECuN{DPxE1?	MorlNVkxOjh2MkS=
HN5	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXKzdZd1PzJiaB?=		NYL1bWNRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkB4cXSqIFXDOVAhd2ZiMD6wNUDPxE1?	Mnn1NVkxOjh2MkS=
BA/F3	NXTEUoI2S3m2b4TvfIlkKEG\|c3H5		MknaO\|IhcA>?		MlG3R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCC5aYToJGlEPTBib3[gNE4xOTB6IN88US=>	NHXacJAyQTJ\|OUKyPS=>
NIH3T3	M4\0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX\McXhSPzJiaB?=		Ml3PS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	Mn\ZNVk3PjV\|N{e=
MCF7 MX	NVfEelBwTnWwY4Tpc44hSXO\|YYm=		M2nwSVMxKG2rbh?=		M1HVXmlvcGmkaYTpc44hd2ZiQlPSVEBmgHC{ZYPz[YQhf2m2aDDJR\|UxKG:oIEGuNUDPxE1?	M320Z\|E6QTN{OU[w
A431	NYDx[IZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfkOWIyOCEQvF2=	MYG3NkBp		MmHLS2k2OD1yLkWxOEDPxE1?	NV;tOmJROTl7Nkm0OlU>
A431	MWLLbY5ie2ViQYPzZZk>	M4DWWVAvOSEQvF2=	MY[xJIg>		M1nzUGlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>	MV[xPVk3QTR4NR?=
A431	MVXLbY5ie2ViQYPzZZk>	MYGxNFAh\|ryP	MYKxNEBucW5?		NFX1fJVRem:ub37n[YQhcW6qaXLpeI9zgSCjY4Tpeol1gSCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?	M1G0WlE6QTZ7NE[1
Sf9	M3PteGtqdmG\|ZTDBd5NigQ>?		M2DWWFExKG2rbh?=	MnG2SG1UVw>?	NG\qU3BKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemWlZYD0c5Ih[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzNizszN	MVOyNFA2PjR{NR?=
NCI-H1975	NV\zcI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXGXZA2KM7:TR?=	MYe3NkBp		M3SxRmlEPTB;OD6yOkDPxE1?	M{DN[VIxOTVzNkew
NCI-H1975	NELoPZNMcW6jc3WgRZN{[Xl?	M{TJ[\|ExKM7:TR?=			M2T5cGlvcGmkaYTpc44hd2ZiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9v	M1e2elIxOTVzNkew
NCI-H1975	NV\PXotOTnWwY4Tpc44hSXO\|YYm=	NWXNPHJ6OTBizszN			M3\TeGlvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NVzuZWFjOjBzNUG2O\|A>
NCI-H1975	NIniV5ZHfW6ldHnvckBCe3OjeR?=	NEnZUIQ2KM7:TR?=	MUC0PEBp		MXLJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGG\|c3Xzd4VlKGG\|IHHjeIl3[XSrb36gc4Yh[2G\|cHHz[U0{	NWDidItPOjBzNUG2O\|A>
A375	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NU\zTG5EPDhiaB?=		M{i3VGlEPTB;MkCuOVUh\|ryP	NGPzeFYzODNyNEWzOy=>
SMMC7721	M2DEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX3ITpRQPDhiaB?=		MlzMTWM2OD1\|Mz6xNkDPxE1?	NGWwPG8zODNyNEWzOy=>
DU145	M{PBXGN6fG:2b4jpZ{BCe3OjeR?=		NWfVcnJDPSCm	NF7INHpFVVOR	MlnCTWM2OD12Mj6xO{DPxE1?	M4fBb\|IxPDZ4NUW1
MIAPaCa2	MYjDfZRwfG:6aXOgRZN{[Xl?		MlzROUBl	Mln3SG1UVw>?	Ml\aTWM2OD13MD62NkDPxE1?	NEPjcYEzODR4NkW1OS=>
PANC1	MU\DfZRwfG:6aXOgRZN{[Xl?		NVXMNFFqPSCm	NGjKfYdFVVOR	NH7xWZZKSzVyPUSwMlQzKM7:TR?=	M4D5XVIxPDZ4NUW1
PC9	M2e1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe2RVlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGVITlJvZHXmbYNq\W62IHj1cYFvKFCFOTDj[YxteyC5aYToJGVEPTBib3[gNE4xOTdizszN	MV[yNVIxQDhyMh?=
PC9	NVrWPFliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXmSpBjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	MlLjNlEzODh6MEK=
PC3	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTUNVAh\|ryP	MlrxO\|IhcA>?	NF63OZBFVVOR	NI\0d5hKSzVyPUeuOEDPxE1?	NIW2TXEzOTN3M{W0Oi=>
MDA-MB-468	M3njVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\Gc4oyODBizszN	MmjZOFghcA>?	NHfM[oxFVVOR	NUPJdmZOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJk>	M{\xc\|IyPDJ7NkOy
Plasmodium falciparum					M1HxOZFJXFNicILv[oltcW6pIH\vdkBqdmirYnn0c5J{KG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBxem:uaX\ldoF1cW:w	MWSyNVgyPzB2NR?=
NCI-H1993	M2XYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTjO\|IhcA>?	M2qycGROW09?	MoTmTWM2OD1yLkGg{txO	M1:wPVIyQTF4NEOz
NCI-H292	MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlfhO\|IhcA>?	NY\Eb\|NGTE2VTx?=	MmHQTWM2OD1yLkCyJO69VQ>?	M3X6d\|IyQTF4NEOz
A431	NXfZc2JlU2mwYYPlJGF{e2G7		M2nyd\|IhcA>?	NIXTOIJFVVOR	Mnj2TY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCDNEOxJJdqfGhiSVO1NEBw\iByLkCwNUDPxE1?	Ml3MNlIyODFzM{K=
MCF7	NY\nR5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPsSJIyODEEoN88[{9uVA>?	NVHvVJRFPDhiaB?=	NUjTT3dTTE2VTx?=	MnrwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKg[4Vv\SC5aYToJGlEPTBib3[gNVIvODVizszN	NVTLeXFjOjJzMUmxN\|A>
BT474	NESzc3BEgXSxdH;4bYMhSXO\|YYm=	NY\CS\|RwOTBizszN	NUDjRpZIPDhiaB?=		NF7BcYhEgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIFLUOFc1KGOnbHzz	M4niN\|IzOTN6M{C4
MCF7	M{PDRWN6fG:2b4jpZ{BCe3OjeR?=	MonJNVAh\|ryP	M1OxWFQ5KGh?		M{XWZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=	MmnCNlIyOzh\|MEi=
HCC827	MYDLbY5ie2ViQYPzZZk>	NYf6PHRGOC5zMkWg{txO	NYT2VoRJOjRiaB?=	M1TtT2ROW09?	MVHJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQhYTFyNkigZZV1d3Cqb4PwbI9zgWyjdHnvci=>	M{\ZPVIzOzN7M{Sy
HCC827	M1TFTGtqdmG\|ZTDBd5NigQ>?	NEjhVYMxNjF{NTFOwG0>	NY\qe5hROjRiaB?=	MmHqSG1UVw>?	M3HtbGlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	MXyyNlM{QTN2Mh?=
HCC827	NIPV[2hMcW6jc3WgRZN{[Xl?	NYPD[XROOC5zMkWg{txO	M3rIXFI1KGh?	MVjEUXNQ	Ml7wTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	NHXQelkzOjN\|OUO0Ni=>
A431	MUjLbY5ie2ViQYPzZZk>	NEm3fIUyODBizszN	MojnN\|AhdWmw		NGX3bI9KdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	MoOyNlI3QTh5OEK=
H460	M{PxbmN6fG:2b4jpZ{BCe3OjeR?=		NInyZmQ4OiCq		M3zMeGlEPTB;NT61PUDPxE1?	NWfrNWZxOjJ5Mke0OFk>
HT-29	NGT3OZBEgXSxdH;4bYMhSXO\|YYm=		NXv6VHR5PzJiaB?=		Mnj3TWM2OD1\|LkO2JO69VQ>?	NVPrbZJCOjJ5Mke0OFk>
SGC7901	M2LqeGN6fG:2b4jpZ{BCe3OjeR?=		NUjzSVFMPzJiaB?=		NWTUV2JMUUN3ME2xNE4zPiEQvF2=	M{TQXFIzPzJ5NES5
A498	NYPve2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELRNJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHu[EBUWkNid3n0bEBKSzVyIH;mJFgvPiEQvF2=	MlqzNlI5OTh6NEi=
Calu3	MWPDfZRwfG:6aXOgRZN{[Xl?	NVvDZ24xOTBizsznM41N	MVu3NkBp		MkTuTWM2OD1zLk[g{txO	NGThfVQzOzFzNkG2PC=>
FADU	M3nxdGN6fG:2b4jpZ{BCe3OjeR?=	NXrXO5NJOTBizsznM41N	NV;LUZlTPzJiaB?=		MYTJR\|UxRTBwMEWg{txO	NUGycHZXOjNzMU[xOlg>
HCC827	MkDnR5l1d3SxeHnjJGF{e2G7	NH3qfZoyOCEQvHevcWw>	NWTv[4NGPzJiaB?=		M{\vR2lEPTB;MD6wNFE2KM7:TR?=	M4O3fFI{OTF4MU[4
PC9	NW[xbVM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzQZ2RpOTBizsznM41N	MXG3NkBp		MYnJR\|UxRTBwMEG0JO69VQ>?	MVSyN\|EyPjF4OB?=
Sf9	M163b2tqdmG\|ZTDBd5NigQ>?		NIHMN\|UyKGh?	M4DwRmROW09?	M2[yeGlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLYTh[4dm\CCHR1\SJGw5OzSUIH31eIFvfCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODF3IN88US=>	NXvaWmVzOjN4MUG2PVE>
16HBE14o-	MkjxR5l1d3SxeHnjJGF{e2G7	MWixNEDPxE1?	NHvMbYw4OiCq	NUfYV\|VGTE2VTx?=	MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>	MWeyN\|Y3QDR2MR?=
NCI-H1975	NEW4PIFEgXSxdH;4bYMhSXO\|YYm=	NYTi[ohHOTBizszN	Ml31O\|IhcA>?	MlPVSG1UVw>?	MofiR5l1d3SxeHnjbZR6KGGpYXnud5Qh\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhPi57MUeg{txO	NWfJZZpmOjN4Nki0OFE>
16HBE	NWjWUHY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHf5ZmU4OiCq	NIjPboxFVVOR	NITBUY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	MV:yN\|c6OjNzOB?=
16HBE	NWTyWFNqTnWwY4Tpc44hSXO\|YYm=	M3rHdlExOCEQvF2=	MYexOVAhdWmw	MmG3SG1UVw>?	NGTxcXVKdmS3Y4Tpc44hd2Zibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44hcW5iaIXtZY4hOT[KQlWgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgSWdHWg>?	NVjoV2VHOjN5OUKzNVg>
A549	NVfVTlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEX6NYc4OiCq	MlLCSG1UVw>?	MmL1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh\|ryP	M4GzTlI{Pzl{M{G4
SH-SY5Y	NWDS[VFTS3m2b4TvfIlkKEG\|c3H5		NEDXR\|I4OiCq		M3e4VmlEPTB;MUiuNlEh\|ryP	NWXHb3pROjN6N{G5NFk>
LoVo	MoPYT4lv[XOnIFHzd4F6		MlWxNkAhcA>?	M4DWOWROW09?	MnHrTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yNkKg{txO	NEPDOYQzOzl\|MEm5OC=>
PC9	MnHET4lv[XOnIFHzd4F6		NWPVSHdIOiCq	NHPWPZhFVVOR	MYrJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDhZ5RqfmG2aX7nJI12fGGwdDDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUFO5JINmdGy\|IIfpeIghUUN3MDDv[kAxNjByOEeg{txO	NEW0PZIzOzl\|MEm5OC=>
HCC827	NFKzXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX:4W3hLPzJiaB?=		M4i0WWlEPTB;MD6wNVIh\|ryP	NGrSWGIzOzl5M{G2PC=>
A549	NF7NPWFMcW6jc3WgRZN{[Xl?	NUfmfYwxOSEQvF2=	NHH0U48yKGh?	NVvtZ4NFTE2VTx?=	NEXURolKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzl7IN88US=>	MlXiNlM6QDh\|NUS=
A549	MW\GeY5kfGmxbjDBd5NigQ>?	M3;jVlEh\|ryP	NXv4Z2lrOSCq	MVLEUXNQ	NX3YN5FyS2WubIXsZZIhfXC2YXvl	NYnZ[ol3OjN7OEizOVQ>
HCC827	M2\uSGtqdmG\|ZTDBd5NigQ>?	MkPXNE42KM7:TR?=	M4LJ[VIhcA>?	NEG2[m9FVVOR	NHTVNW1KdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	MXKyN\|k6OzN{OB?=
HCC827	Mo\USpVv[3Srb36gRZN{[Xl?	M1jDPVAvPSEQvF2=	NF;Q[4kzKGh?	MXHEUXNQ	NEPU[5pKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	Mo\SNlM6QTN\|Mki=
HCC827	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP2TZlxOTBizszN	MXu3NkBp	M1LheWROW09?	MojZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	NX7h[Zp1OjRyNUO2O\|Q>
A431	M1rub2tqdmG\|ZTDBd5NigQ>?	Mm\xNVAxKM7:TR?=	MmGwN\|AhdWmw		MkCzTY5pcWKrdHnvckBw\iCHR1\SJIlvKHOqZXSgcYVu[nKjbnWgeoV{cWOuZYOge4l1cCCLQ{WwJI9nKDFwMTFOwG0>	NUW1OZJrOjRyOUS0N\|I>
BCRP-MDCK2	M3SwbmZ2dmO2aX;uJGF{e2G7	M3[4R\|EvQCEQvF2=	NVHRUIxmPzJiaB?=	MXTEUXNQ	MX\JcoNz\WG\|ZTDv[kBxdGG\|bXGgcYVu[nKjbnWg[ZhxemW\|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>	M3zodFI1OTh2MkGz
BCRP-MDCK2	NVHXfHMxTnWwY4Tpc44hSXO\|YYm=	NILOfI0yNjhizszN	MmjsO\|IhcA>?	NUjqd3NDTE2VTx?=	M2iySnJm\HWldHnvckBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	M{C4OFI1OTh2MkGz
MDCK	MVHDfZRwfG:6aXOgRZN{[Xl?		MWS3NkBp	M3e2PGROW09?	NEPtUldIUTVyPUGuOFUh\|ryP	M37MclI1OTh2MkGz
MDCK2	NVHCemdkTnWwY4Tpc44hSXO\|YYm=	MkXRNU45KM7:TR?=	Mo[0O\|IhcA>?	NYGyeo9mTE2VTx?=	M2raW2lvcGmkaYTpc44hd2ZiaIXtZY4hSkOUUDDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMhUG:nY3jzeEA{OzN2MjDhZ4N2dXWuYYTpc44hf2m2aDDJR\|UxKG:oIEOuNVkh\|ryP	NEKwc3gzPDF6NEKxNy=>
A431	M1jmXGN6fG:2b4jpZ{BCe3OjeR?=		Mn7FO\|IhcA>?	MVvEUXNQ	MmHlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	NYTCXY5IOjR2MUGxNlM>
Calu3	NHjSdGFEgXSxdH;4bYMhSXO\|YYm=		NUflVVZVPzJiaB?=	M3XPWmROW09?	MnHXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FtfTNiY3XscJMh\XiycnXzd4lv\yCKRWKyJJdqfGhiSVO1NEBw\iByLkm5JO69VQ>?	NFn0V5YzPDRzMUGyNy=>
KB	NIjnSWNMcW6jc3WgRZN{[Xl?	MofENVAh\|ryP	NFn2W\|UyKGh?	NWDNN3g2TE2VTx?=	NXTkN3lVUW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJid3n0bEBKSzVyIH;mJFAvODJ3IN88US=>	NIjacFIzPDRzMUGyNy=>
BEAS2B	M1y3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYC1NEDPxE1?	MnO5O\|IhcA>?	NXPvU2k5TE2VTx?=	MUDJR\|UxRTF\|Lkm0JO69VQ>?	M3zrc\|I1PjB5NUmx
NCI-H1975	MWLGeY5kfGmxbjDBd5NigQ>?	MYexNFAh\|ryP	MYmxOVAhdWmw	MnHnSG1UVw>?	MXXJcoR2[3Srb36gc4YhVk9icILv[JVkfGmxbjDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NXGxS2RIOjR4MEe1PVE>
Hela	M{S2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYKyOEBp	NInRU\|FFVVOR	M2DMbGlEPTB;Mj62O{DPxE1?	NH7ofWczPDd\|MUK4NS=>
HepG2	Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTvNlQhcA>?	MknQSG1UVw>?	NFrhUYRKSzVyPU[uOFIh\|ryP	NX;VZXlrOjR5M{GyPFE>
Sf9	NH;v[\|lMcW6jc3WgRZN{[Xl?		MofxNVAhdWmw	NEfSeVNFVVOR	NYfNZpdFUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IHjpd{11[WepZXSgSWdHWiBqYX3pco8h[WOrZDC2OFUuOTF6Njmg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?	M1nsbVI1PzNzMkix
SW620	MUjDfZRwfG:6aXOgRZN{[Xl?		NV\Xbmp6PDhiaB?=	M3Pn[2ROW09?	NYfsOYJvUUN3ME2yPE4zKM7:TR?=	NF:3bnEzPDlyMEW5OC=>
HCC827	NIrDN25HfW6ldHnvckBCe3OjeR?=	M1P6RVAvPSEQvF2=	MWiyJIg>	MXvEUXNQ	NWPzfmxo\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHLWEBxcG:\|cHjvdplt[XSrb36=	NGrEVnUzOzl7M{OyPC=>
HCC827	MXjGeY5kfGmxbjDBd5NigQ>?	NGH4SYkxNjVizszN	NV7MeGo5OiCq	MUDEUXNQ	MWrkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=	MVWyN\|k6OzN{OB?=
HCC827	M1judWN6fG:2b4jpZ{BCe3OjeR?=	NV3vT3RyOC53IN88US=>	NHLXdVc4OiCq	Mm\pSG1UVw>?	M1nxZ4hieyCwbzDjfZRwfG:6aXPpeJk>	NX\DO\|FyOjN7OUOzNlg>
NCI-H1975	MmC2SpVv[3Srb36gRZN{[Xl?	NUXLNFVIOTBizszN	NFuw[HI5KGh?	MXnEUXNQ	NFTufIZld2W\|IH7veEBqdmirYnn0bUBGT0[UIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:w	M3fVXFI{OTF4MU[4
A431	MXjLbY5ie2ViQYPzZZk>	M4\a[VEh\|ryP	NVro[3hGOSCq	NID6eoZFVVOR	NHzQbVNp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	NYqxWohLOjR7MEC1PVQ>
LNCaP	NHrXWVZHfW6ldHnvckBCe3OjeR?=	M3rFSFExKM7:TR?=	NFm0RlEzcCCxcjC0JIg>	M3nTUGROW09?	NYTEbnh2\G:nczDuc5QhcW6qaXLpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIHntcZVvd3C3cnnmbYVlKG[uYXeteIFo\2WmIFLtfEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|MmDdRXRR	MlSyNVg3Pjd\|MUK=
H1975	M4KxfGtqdmG\|ZTDBd5NigQ>?	NEPK[mkyKM7:TR?=	M4e4SlI1KGh?	NIHrcZRFVVOR	NULlS3VU\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	NVPMUWNXOjR4MEe1PVE>
H1975	NHXKVGFHfW6ldHnvckBCe3OjeR?=	M1;kPFEh\|ryP	MlO4NlQhcA>?	MX;EUXNQ	NVPNW2wx\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCP	NH3lbnMzPDZyN{W5NS=>
HCC827	NIi1S4NMcW6jc3WgRZN{[Xl?	M4PUflAvOTFizszN	NYXFWFBDOSCq	MXzEUXNQ	NYi0Z2JicGG\|IH7vJIlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGVITlJiYYPz[ZN{\WRiYYOgdoVkd3[ncomgc4YhTUeIUjDheZRweGixc4Doc5J6dGG2aX;u	MlTKNlQyOjR6OUi=
H1975	NE[xUpZMcW6jc3WgRZN{[Xl?	NUPUSGJwOC5\|MzFOwG0>	Ml3yNkBp	MlPPSG1UVw>?	NUG1RYhM\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25?	MXGyOFEzPDh7OB?=
H1975	MYrLbY5ie2ViQYPzZZk>	MUGwMlM{KM7:TR?=	M4\wTFIhcA>?	NVmy[WxRTE2VTx?=	NHj4[2xld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	NHT2UoozPDF{NEi5PC=>
H1975	MWXLbY5ie2ViQYPzZZk>	MXiwMlM{KM7:TR?=	MmnZNkBp	MonNSG1UVw>?	MXvkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36=	NFjuOmgzPDF{NEi5PC=>
H1975	NUnHc2NxU2mwYYPlJGF{e2G7	NYHyNIs5OC5zMkWg{txO	M1Tt[\|I1KGh?	MWnEUXNQ	NWnTPY9G\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdDDZNVA3QCCjdYTvdIhwe3Cqb4L5cIF1cW:w	NGG2UmIzOjN\|OUO0Ni=>
H1975	M4P1UGtqdmG\|ZTDBd5NigQ>?	M3zjTVAvPSEQvF2=	NGqwbXozPCCq	M{fZPGROW09?	NEjJWllld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	MlHaNlI{Ozl\|NEK=
H1975	M4jpXWtqdmG\|ZTDBd5NigQ>?	NWnEOJlsOC53IN88US=>	NUP4ZWRTOjRiaB?=	M{jtXGROW09?	MlPY[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	Mn3JNlI{Ozl\|NEK=
MIAPaCa2	NUDLWmtVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWyMlUh\|ryP	MkHaO\|IhcA>?	MVvEUXNQ	NUT2UIFJcGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	MWCyNFQ3PjV3NR?=
MIAPaCa2	NIT0TW9EgXSxdH;4bYMhSXO\|YYm=	MYGxJO69VQ>?	NXfCd5E4OTBiZB?=	NWXRO2N2TE2VTx?=	M2rDVohieyCwbzDjfZRwfG:6aXPpeJkh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>	NUj4XYNnOjB2Nk[1OVU>
MIAPaCa2	MVjBdI9xfG:\|aYOgRZN{[Xl?	M2rhVFExKM7:TR?=	M3vDTVI1cCCxcjC0PEBp	MVLEUXNQ	NUHCTlJ7\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	NHrrd4MzODR4NkW1OS=>
MIAPaCa2	NIO4ZYRCeG:ydH;zbZMhSXO\|YYm=	NUHMO5Y5OjBizszN	M{WzRlI1KGh?	MYfEUXNQ	Ml[2[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk[XOyYYPlJFMh[WO2aY\heIlwdg>?	MV2yNFQ3PjV3NR?=
EoL-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPQTWM2OD13LkG3JI5O	NHHNPIJUSU6JRWK=
NCI-H720	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWq1Zoc4UUN3ME2yOk46OiCwTR?=	NHPBfIVUSU6JRWK=
NCI-SNU-5	M2q1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIryeYRKSzVyPUK4MlE6KG6P	MnPGV2FPT0WU
EW-3	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33IV2lEPTB;NE[uNFQhdk1?	Mn7HV2FPT0WU
HCC2218	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LFTmlEPTB;NUCuOVkhdk1?	NF[xflJUSU6JRWK=
HuO-3N1	MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTV4LkC5JI5O	NVrXOVVjW0GQR1XS
DB	NHXOSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPnSVF4UUN3ME22NE46PiCwTR?=	NYK1UnJmW0GQR1XS
HSC-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonwTWM2OD14MT61N{BvVQ>?	Ml\TV2FPT0WU
DOK	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTl\|Lk[yJI5O	M4W0RXNCVkeHUh?=
H9	M2LUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TFbWlEPTB;MUO3MlIhdk1?	MWLTRW5ITVJ?
NCI-H292	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHkTWM2OD1zNkKuOlYhdk1?	M3mxZXNCVkeHUh?=
HSC-2	M3uxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnG0TWM2OD1zNkWuOVchdk1?	NGXxPVRUSU6JRWK=
LU-65	NXXmNppzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF4Nj62NUBvVQ>?	M3jaRnNCVkeHUh?=
BV-173	NGXpWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF6Nj61OUBvVQ>?	NV;pcWIzW0GQR1XS
LB2241-RCC	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TDb2lEPTB;MUm0Mlk{KG6P	M3;Ub3NCVkeHUh?=
KG-1	NUTZOog1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXUPXVwUUN3ME2yNFQvOzRibl2=	M{n2T3NCVkeHUh?=
CHL-1	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1uwUWlEPTB;MkC4MlUyKG6P	MYLTRW5ITVJ?
KYSE-140	NGrWcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfJcG9IUUN3ME2yNFkvQTZibl2=	MoHUV2FPT0WU
DU-145	NHXkPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJzOT6wOEBvVQ>?	NHXxRm5USU6JRWK=
EW-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\tTWM2OD1{MkWuNUBvVQ>?	MWrTRW5ITVJ?
KYSE-450	NVS3VVJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPpTWM2OD1{NEeuPVIhdk1?	MYnTRW5ITVJ?
CAL-72	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknzTWM2OD1{NkiuO\|Mhdk1?	MUHTRW5ITVJ?
MEG-01	M4j1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1qzfWlEPTB;Mke2Mlc3KG6P	MkLxV2FPT0WU
HCE-T	NUO2NHpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGD1T4JKSzVyPUK3PU44QSCwTR?=	MnOyV2FPT0WU
NCI-SNU-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmP5TWM2OD1{OEOuN\|Ihdk1?	MULTRW5ITVJ?
CAL-27	NI\3VplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3y5TWlEPTB;Mki5MlA5KG6P	M1OyS3NCVkeHUh?=
BALL-1	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{m1NGlEPTB;Mkm3MlQzKG6P	MWnTRW5ITVJ?
SBC-1	M4HhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17FSGlEPTB;M{C3Mlc6KG6P	M2jNU3NCVkeHUh?=
CAL-54	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4n0e2lEPTB;M{GxMlI{KG6P	MlzMV2FPT0WU
TI-73	MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHFZoVKSzVyPUOxNk44PSCwTR?=	M3Pj[nNCVkeHUh?=
P12-ICHIKAWA	NV;qWmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4f5NWlEPTB;M{K4MlA3KG6P	MljFV2FPT0WU
ACHN	M3PUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTONpNKSzVyPUOzNU41KG6P	NYrnSZAzW0GQR1XS
PC-14	NXPyfo9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HFV2lEPTB;M{OzMlQyKG6P	MnftV2FPT0WU
HCC1806	NW\2OIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDvSG1KSzVyPUOzO{42OSCwTR?=	MnHGV2FPT0WU
SK-MEL-24	NFHzOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXiS\|NKSzVyPUOzO{45PyCwTR?=	M3HTVXNCVkeHUh?=
A4-Fuk	M3nr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr5c\|ZKSzVyPUO1NE4xOiCwTR?=	M1vZfnNCVkeHUh?=
ECC10	NXv2So9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHH0[\|FKSzVyPUO1Nk46PiCwTR?=	NE\Me4xUSU6JRWK=
KASUMI-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfZWYJXUUN3ME2zOlYvPzNibl2=	MUnTRW5ITVJ?
CAL-33	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;GR2lEPTB;M{ewMlkhdk1?	NXewZYhlW0GQR1XS
MDA-MB-175-VII	NVf5SJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHsNpJWUUN3ME2zO\|gvQDhibl2=	MmO1V2FPT0WU
NUGC-3	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTRyMT64NUBvVQ>?	NEfPWZVUSU6JRWK=
KY821	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rYN2lEPTB;NEC4MlU4KG6P	NUnvVYlEW0GQR1XS
CTB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLHTWM2OD12MkSuOEBvVQ>?	MnqwV2FPT0WU
DoTc2-4510	NG\nXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTR2Mj6xNkBvVQ>?	MUXTRW5ITVJ?
EFO-27	NYq4Z\|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnuNIVKSzVyPUS1OE44PCCwTR?=	M{XuO3NCVkeHUh?=
BPH-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1j0RWlEPTB;NEmxMlE3KG6P	MXvTRW5ITVJ?
KYSE-270	NWXtR3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjmNmVlUUN3ME20PVgvPjVibl2=	NX\NWm44W0GQR1XS
HO-1-N-1	Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmS1TWM2OD13MEmuNlUhdk1?	M4HWWXNCVkeHUh?=
SK-MEL-1	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jofmlEPTB;NUGwMlk6KG6P	NWTlO29IW0GQR1XS
MOLT-13	NGfrW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDZ[FRUUUN3ME21NVQvQDJibl2=	NIfleHJUSU6JRWK=
TK10	NXe0NGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nofmlEPTB;NUG1MlEyKG6P	NHH0TmdUSU6JRWK=
HN	NX32UZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzHSYdpUUN3ME21NVcvOzhibl2=	NUDqO4VsW0GQR1XS
SCC-15	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\GTWM2OD13MkWuOlghdk1?	M3W0OXNCVkeHUh?=
NCI-H358	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITTNZpKSzVyPUWyO{43PiCwTR?=	M3;sWXNCVkeHUh?=
KYSE-180	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD2TWM2OD13M{CuOlIhdk1?	MVjTRW5ITVJ?
NCI-H82	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS4RmpCUUN3ME21OFAvPSCwTR?=	M1rEbXNCVkeHUh?=
NB7	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3heFVtUUN3ME21OFYvOzJibl2=	NXjNcVVbW0GQR1XS
DSH1	NHH4dVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[yTWM2OD13Nk[uPFghdk1?	M1\qd3NCVkeHUh?=
RS4-11	NX;wOJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULmOYpzUUN3ME21OlgvPTlibl2=	MYjTRW5ITVJ?
CAN	M1Kz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[0d2lEPTB;NUiwMlc3KG6P	M2fIe3NCVkeHUh?=
Ca9-22	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTV6OD62OEBvVQ>?	MV3TRW5ITVJ?
CAL-39	NUK3RXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnzTWM2OD13OU[uN{BvVQ>?	NWPVUoFSW0GQR1XS
NCI-H1623	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTV7OT6zOkBvVQ>?	MmrTV2FPT0WU
FADU	M33ZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoS0TWM2OD14MESuOlkhdk1?	M{POdXNCVkeHUh?=
NB69	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\CcI5lUUN3ME22NVQvOzVibl2=	MYfTRW5ITVJ?
Ramos-2G6-4C10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnn4TWM2OD14MkGuOFYhdk1?	NWnhUogzW0GQR1XS
LB1047-RCC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjldo5lUUN3ME22NlUvOjlibl2=	NFLDXZlUSU6JRWK=
MV-4-11	NX[xV4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HodWlEPTB;NkK3Mlchdk1?	MYLTRW5ITVJ?
DBTRG-05MG	NFLne4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTZ\|Mj6yPEBvVQ>?	MVrTRW5ITVJ?
ME-180	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTZ\|Mj65JI5O	M37OZ3NCVkeHUh?=
NBsusSR	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlznTWM2OD14NE[uOVIhdk1?	M{XFfnNCVkeHUh?=
COR-L105	M2fT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33iWWlEPTB;Nk[yMlU{KG6P	MnWxV2FPT0WU
ETK-1	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rWRmlEPTB;Nk[yMlU6KG6P	NG\ibGVUSU6JRWK=
L-363	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\B[4N4UUN3ME22O\|EvQTRibl2=	MYrTRW5ITVJ?
LU-134-A	NXfjbZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnSxTWM2OD15MUmuNFkhdk1?	MXnTRW5ITVJ?
NCI-H1770	M1KyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTzV201UUN3ME23NlIvPCCwTR?=	NET1ZVRUSU6JRWK=
HAL-01	NFm4SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTd\|ND63NUBvVQ>?	MVHTRW5ITVJ?
COLO-684	MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\hfWlEPTB;N{WzMlAyKG6P	MmDhV2FPT0WU
TE-6	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTd4ND6zNUBvVQ>?	Mlr5V2FPT0WU
A431	NWTYT5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLCXFlpUUN3ME23PFAvODRibl2=	MnP6V2FPT0WU
LU-135	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\XPI1KSzVyPUe4N{4xOyCwTR?=	M2jwS3NCVkeHUh?=
EC-GI-10	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1n2eWlEPTB;N{i4MlUzKG6P	MlPHV2FPT0WU
TE-12	NIDzWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHy4d5NKSzVyPUiyNU4yOSCwTR?=	MkXIV2FPT0WU
LoVo	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3joUWlEPTB;OEW5MlA3KG6P	Mli1V2FPT0WU
23132-87	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDZO3NWUUN3ME24OlQvOjhibl2=	NYrCVnpxW0GQR1XS
AU565	NHz5cWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLNd\|ZKSzVyPUi2PU43KG6P	M4fTd3NCVkeHUh?=
DEL	M1jrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWOwfZVuUUN3ME24O\|cvPjVibl2=	MnzOV2FPT0WU
COR-L88	M4DpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTh6Mj6yOkBvVQ>?	MkDmV2FPT0WU
NCI-H2126	NHz0NplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFOyTJZKSzVyPUi4Nk45OyCwTR?=	M1vDb3NCVkeHUh?=
CAPAN-1	NXzPe4tvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTnTWM2OD16OEOuNlkhdk1?	NWDONVZtW0GQR1XS
BT-474	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrRTWM2OD17M{iuNVQhdk1?	Mof4V2FPT0WU
BHY	M2XX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjjOldlUUN3ME25O\|UvPDhibl2=	MVXTRW5ITVJ?
HT-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TIbWlEPTB;OUiyMlQyKG6P	MoPXV2FPT0WU
SK-NEP-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XqSGlEPTB;OUi5MlQ1KG6P	MlTQV2FPT0WU
MS-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Tj[WlEPTB;OUm0MlY6KG6P	NVT4VFB2W0GQR1XS
DOHH-2	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTFwMECwNlEh\|ryP	NInTd3FUSU6JRWK=
NCI-H1304	NYCzXW8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV25cpM6UUN3ME2xMlAyPjR\|IN88US=>	MXzTRW5ITVJ?
EM-2	NVf3UG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYG4PXU5UUN3ME2xMlA{ODF4IN88US=>	MXrTRW5ITVJ?
MHH-PREB-1	NI[we2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVSx[5BRUUN3ME2xMlA5PDVzIN88US=>	M1e2W3NCVkeHUh?=
KU-19-19	M2LoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFwMEi1OFEh\|ryP	NUjNcmdHW0GQR1XS
NCI-H1648	NGjUV\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwMUC2NVYh\|ryP	NVjHTW9uW0GQR1XS
MKN1	NUXTOXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrCTWM2OD1zLkKxPVg4KM7:TR?=	M3fuT3NCVkeHUh?=
SNU-449	NHSxVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\uTWM2OD1zLkKyNlA5KM7:TR?=	NVjQdVJzW0GQR1XS
OAW-42	NGXEVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPucotKSzVyPUGuNlc5OjVizszN	NXHwd3dpW0GQR1XS
769-P	NHvYXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDDTWM2OD1zLkK3PVE5KM7:TR?=	NHjpVFZUSU6JRWK=
SW1088	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTFwMkm2NFch\|ryP	M4\5THNCVkeHUh?=
GCIY	NIT6PYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFwM{CxN\|Ih\|ryP	NF;wPFJUSU6JRWK=
CTV-1	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mom1TWM2OD1zLkOwPEDPxE1?	NELvPGNUSU6JRWK=
NCI-H1092	NVvPcnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\tTWM2OD1zLkOwPFUh\|ryP	NX\iT5I6W0GQR1XS
NKM-1	M{jJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPpc3lQUUN3ME2xMlMzPTl5IN88US=>	MXLTRW5ITVJ?
NCI-H1650	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LCSmlEPTB;MT6zN\|Q5OiEQvF2=	MXrTRW5ITVJ?
SW954	NVTqSXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPUTWM2OD1zLkO0NFQ5KM7:TR?=	NI[z[IZUSU6JRWK=
SW48	M2XUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFwM{[2NVgh\|ryP	NV;CR4k5W0GQR1XS
SK-N-DZ	NULpfnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwM{[5OFch\|ryP	M4K0UHNCVkeHUh?=
KMOE-2	M131W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGOyVmNKSzVyPUGuN\|k5OTVizszN	MXjTRW5ITVJ?
NB5	NFm0Uo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTFwNEC4PVQh\|ryP	NUHRW\|FtW0GQR1XS
CCRF-CEM	NVfLNYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\CZ2lEPTB;MT60NVEyKM7:TR?=	NGX5ZmRUSU6JRWK=
RH-1	M1fpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULuUXVDUUN3ME2xMlQyOTN4IN88US=>	MYnTRW5ITVJ?
NCI-H526	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzoXFRKSzVyPUGuOFM5OjZizszN	Ml63V2FPT0WU
697	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrLSmlKSzVyPUGuOFQyODRizszN	Mo\4V2FPT0WU
J82	NUDxR2dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnmNZVKSzVyPUGuOFU4PjZizszN	M3TaUnNCVkeHUh?=
BE-13	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\YTWM2OD1zLkWwOlcyKM7:TR?=	M2rTW3NCVkeHUh?=
SAS	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEWwVHRKSzVyPUGuOVE3OjJizszN	MlXXV2FPT0WU
SCC-25	M1zodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\KTWM2OD1zLkWyN\|IzKM7:TR?=	MlTpV2FPT0WU
LAMA-84	M3jOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFwNUO4NVUh\|ryP	NGKwbmVUSU6JRWK=
HSC-3	NELaZ\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorhTWM2OD1zLkW0N\|gh\|ryP	NGr2[GRUSU6JRWK=
BT-549	NF3h[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofxTWM2OD1zLkW4O\|Q4KM7:TR?=	M{X4dnNCVkeHUh?=
ML-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTFwNkSwNlkh\|ryP	M2XpVXNCVkeHUh?=
BB30-HNC	M4raZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwNki5O\|Ih\|ryP	M{DTXXNCVkeHUh?=
PANC-03-27	NYWwVWdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jRXWlEPTB;MT63NFE{QSEQvF2=	M1e0V3NCVkeHUh?=
COLO-678	M{HMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrDOo9sUUN3ME2xMlc{PDR2IN88US=>	MWfTRW5ITVJ?
NCI-H1666	NVjmd49CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4L3d2lEPTB;MT63OFcxPCEQvF2=	MXrTRW5ITVJ?
NCI-H209	NIHQc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnSUpRTUUN3ME2xMlc4OjZ7IN88US=>	NF2yb5hUSU6JRWK=
EPLC-272H	NX6zeWRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\uTHdLUUN3ME2xMlg2PTR7IN88US=>	MYfTRW5ITVJ?
OMC-1	NVfnOIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3e5XWlEPTB;MT65PVg5QCEQvF2=	Mn73V2FPT0WU
HCC70	NFTwWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHCSGRKSzVyPUKuNFA5OTVizszN	MlL3V2FPT0WU
CAL-12T	NUD5VYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDNTWM2OD1{LkCxPFYyKM7:TR?=	NWL1[IozW0GQR1XS
TGBC24TKB	M4nPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnEN4V{UUN3ME2yMlAzQTZzIN88US=>	NYXzRngzW0GQR1XS
EKVX	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnjd2x5UUN3ME2yMlA1QTN7IN88US=>	MXTTRW5ITVJ?
SW1116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTjTWM2OD1{LkC2NFA6KM7:TR?=	MkfIV2FPT0WU
NCI-H2009	M16wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTJwME[yNVQh\|ryP	MoPWV2FPT0WU
RPMI-8866	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LFU2lEPTB;Mj6wPFQ5OSEQvF2=	NIXVc3VUSU6JRWK=
KARPAS-45	M3;V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TjZ2lEPTB;Mj6xNlQ4QSEQvF2=	MmPXV2FPT0WU
RXF393	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoixTWM2OD1{LkGzNFM3KM7:TR?=	M13ncHNCVkeHUh?=
786-0	M1njRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTJeYd1UUN3ME2yMlE5PDB4IN88US=>	NF[5c4FUSU6JRWK=
SCC-4	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTJwMkG3O\|Yh\|ryP	NVzFclAxW0GQR1XS
BT-20	NFvXbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJwMk[3OFQh\|ryP	NVf6fXg3W0GQR1XS
A498	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLVTWM2OD1{LkK5OFE2KM7:TR?=	NVztfoh{W0GQR1XS
IGROV-1	NX7jUnpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVX3cY9XUUN3ME2yMlMyOjN5IN88US=>	NX;0XXNrW0GQR1XS
JVM-3	NYn0U4VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPOeIlKSzVyPUKuN\|Q3PDNizszN	MoD1V2FPT0WU
NCI-H2170	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJwM{S3PFMh\|ryP	MXPTRW5ITVJ?
EW-18	NFK0b49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzvZphKSzVyPUKuN\|U1PzFizszN	NXf5PI5WW0GQR1XS
KU812	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTtZYtVUUN3ME2yMlM3Pzd7IN88US=>	NGG1[IdUSU6JRWK=
NY	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjnN2JMUUN3ME2yMlM4OjdizszN	NYLYVotxW0GQR1XS
HTC-C3	NXPxR3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\j[JpKSzVyPUKuOFIzPjdizszN	MnL6V2FPT0WU
CFPAC-1	NXHFSJo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYf1d5d{UUN3ME2yMlQ{QDZ2IN88US=>	MV7TRW5ITVJ?
HH	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LIXGlEPTB;Mj60PVg2PCEQvF2=	M13IUHNCVkeHUh?=
MKN7	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPUSo1KSzVyPUKuOlI4PDhizszN	NVrQRnVpW0GQR1XS
TE-8	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\PfmlEPTB;Mj62N\|Y2OyEQvF2=	NW[wcWhDW0GQR1XS
MC-IXC	M{DvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\nTWM2OD1{Lk[0OFU{KM7:TR?=	NYj0e3FmW0GQR1XS
DMS-79	NITobVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJwNkmyPFQh\|ryP	NUXUN2VMW0GQR1XS
Detroit562	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkD1TWM2OD1{Lk[5PFQ2KM7:TR?=	NHnGNVBUSU6JRWK=
HuP-T4	NHjOOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvaNlJKSzVyPUKuO\|I5OThizszN	NVnYfHV4W0GQR1XS
QIMR-WIL	NIDOR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLlUXExUUN3ME2yMlc2QTV{IN88US=>	MULTRW5ITVJ?
BB65-RCC	NV\qd21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGntemRKSzVyPUKuPFA4OTNizszN	M2C5e3NCVkeHUh?=
PC-3	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTJwOEOzNVch\|ryP	NXHFcmJHW0GQR1XS
OVCAR-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUX3UWNbUUN3ME2yMlg2PTl2IN88US=>	Mo\hV2FPT0WU
KYSE-510	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJwOE[3PFYh\|ryP	MmTWV2FPT0WU
HC-1	MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LSfWlEPTB;Mj65OFAyOiEQvF2=	NGeyS3BUSU6JRWK=
NCI-H1693	NWfURY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M373emlEPTB;Mj65OVg6PyEQvF2=	M4\5cXNCVkeHUh?=
DU-4475	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXVTWM2OD1{Lkm5NFUzKM7:TR?=	MYLTRW5ITVJ?
COLO-680N	M3LBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFGzRZlKSzVyPUOuNFA1QTVizszN	NWTuXZo6W0GQR1XS
MN-60	NX;McXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjaS3dKSzVyPUOuNFQ6PzRizszN	M{m2cnNCVkeHUh?=
BCPAP	NH3yRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTjTWM2OD1\|LkC4Nlk2KM7:TR?=	NFXqT5ZUSU6JRWK=
647-V	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojzTWM2OD1\|LkG2NlIh\|ryP	MWnTRW5ITVJ?
HT-1376	MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXvTWM2OD1\|LkKwOVA3KM7:TR?=	NWPpfm1jW0GQR1XS
NCI-H1793	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzKcGF6UUN3ME2zMlIyODl6IN88US=>	NYXocYYxW0GQR1XS
SW1463	M{LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTFTWM2OD1\|LkK2NVkzKM7:TR?=	MXTTRW5ITVJ?
NCI-H727	MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljtTWM2OD1\|LkO4OVg1KM7:TR?=	NF7JV5BUSU6JRWK=
LB771-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTNwM{mxNlYh\|ryP	MYnTRW5ITVJ?
D-542MG	M3rZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHLb2ZKSzVyPUOuOFQzOjJizszN	NFHNe\|NUSU6JRWK=
NTERA-S-cl-D1	M2Lw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTNwNES5OVch\|ryP	M{LOSnNCVkeHUh?=
C8166	M13YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7YWVJlUUN3ME2zMlQ3PTJzIN88US=>	NFzDcYVUSU6JRWK=
639-V	NHvmTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\LTWM2OD1\|LkW3O\|kzKM7:TR?=	M4[1XHNCVkeHUh?=
TE-1	M3XtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTNwNUmxOlkh\|ryP	NUC3TnNLW0GQR1XS
OAW-28	NFPLV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPDSlZKSzVyPUOuOVk1OjZizszN	NXzaSZVwW0GQR1XS
SK-LU-1	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTNwNkC2OFUh\|ryP	NH3JcVNUSU6JRWK=
CaR-1	M4H6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTNwNkGwOFgh\|ryP	M4XSPHNCVkeHUh?=
A2780	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK0TohpUUN3ME2zMlY1ODh7IN88US=>	M4L0VXNCVkeHUh?=
C2BBe1	M3PYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn2yTWM2OD1\|Lk[0OFA4KM7:TR?=	Mn;PV2FPT0WU
SK-MES-1	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrubmtDUUN3ME2zMlY1PjF2IN88US=>	M3jWdnNCVkeHUh?=
PANC-10-05	NELONm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmr3TWM2OD1\|LkeyNFczKM7:TR?=	MVrTRW5ITVJ?
J-RT3-T3-5	NIjiW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\SN2lEPTB;Mz63OVQxPiEQvF2=	Mme5V2FPT0WU
ES4	NV7re4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLJOlhKSzVyPUOuPFIzQDZizszN	MmfHV2FPT0WU
NCI-H28	NGnmOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPhTWM2OD1\|LkiyPVYyKM7:TR?=	Mnr3V2FPT0WU
NCI-H1155	M2myW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXTUG5KSzVyPUOuPFQyPTlizszN	NVLPS4JiW0GQR1XS
KURAMOCHI	NYjGO\|k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfzTWM2OD1\|Lki2NFU3KM7:TR?=	M4X6S3NCVkeHUh?=
NCI-H69	NWrCO\|h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{G0dWlEPTB;Mz65NFE4QCEQvF2=	NY\T[YlnW0GQR1XS
IST-MES1	NFjmSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\VemlEPTB;Mz65OFAzQSEQvF2=	MV;TRW5ITVJ?
NH-12	NH;qeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTNwOUSxPFch\|ryP	NXjVSWZyW0GQR1XS
JVM-2	NF\xNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHWOVNKSzVyPUOuPVQ4PTJizszN	NFztd45USU6JRWK=
EW-16	NHHlNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFy2SnhKSzVyPUOuPVU2PzdizszN	NXHxSXBVW0GQR1XS
NCI-H441	MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjCSIlKSzVyPUOuPVcxOTRizszN	Mn[4V2FPT0WU
RCC10RGB	NEjscYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzu[nNtUUN3ME20MlAyOjR4IN88US=>	Ml7WV2FPT0WU
TCCSUP	M1jPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnkT2NnUUN3ME20MlEyODVizszN	MXnTRW5ITVJ?
HL-60	NV\PeIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHjVY5SUUN3ME20MlEzOjRzIN88US=>	NXPJ[3hxW0GQR1XS
EW-11	NImxZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVu0Om5iUUN3ME20MlE{OjZzIN88US=>	M{jCZnNCVkeHUh?=
KARPAS-299	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTRwM{GwNVMh\|ryP	M2LaTXNCVkeHUh?=
SNU-C2B	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;GTY1EUUN3ME20MlM1Pjh4IN88US=>	NEDFbWpUSU6JRWK=
LU-139	M13ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL1ZnkyUUN3ME20MlM4OjR5IN88US=>	NGTKd29USU6JRWK=
HCC1937	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTRwM{e5PVMh\|ryP	NHr2enNUSU6JRWK=
GR-ST	NYj1WlI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDLcmhuUUN3ME20MlQ{OThizszN	MYnTRW5ITVJ?
SK-OV-3	NV:1Ro1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHPTWM2OD12LkS2NFQzKM7:TR?=	Ml\wV2FPT0WU
A172	NFj4NZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzrTWM2OD12LkW1OVIyKM7:TR?=	NIDlW3dUSU6JRWK=
NB10	NVzWR4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fi[GlEPTB;ND61PVc5OSEQvF2=	NY[4Rnp1W0GQR1XS
P30-OHK	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLOPVZKUUN3ME20MlgyQTJ7IN88US=>	MkSwV2FPT0WU
KYSE-520	NFq1fmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3u5[GlEPTB;ND64PFAyQCEQvF2=	MlPUV2FPT0WU
KNS-62	NXvRSm94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjaR2hKSzVyPUSuPVA5ODdizszN	MkK2V2FPT0WU
ES1	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPx[lZKSzVyPUSuPVYxOzVizszN	NX7RV4pqW0GQR1XS
KOSC-2	M4HO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXS5XoZ[UUN3ME20Mlk6QTV7IN88US=>	M3nzWXNCVkeHUh?=
TE-9	NVf1N5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXaeW5KSzVyPUWuNFE2OjVizszN	MUDTRW5ITVJ?
NCI-H1838	NV;IOm5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjQ[I5KSzVyPUWuNFIxPzZizszN	NV\WRmh{W0GQR1XS
KP-N-YN	NEG5O5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljGTWM2OD13LkGyOVkyKM7:TR?=	MnPrV2FPT0WU
ALL-PO	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7VPGhKSzVyPUWuNlI2QDdizszN	NInxPGlUSU6JRWK=
NOMO-1	NYHqVpZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlqxTWM2OD13LkKzNVc3KM7:TR?=	NHnMOoNUSU6JRWK=
CGTH-W-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTVwM{i1PFQh\|ryP	MmLaV2FPT0WU
ATN-1	M3HWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\DXWlEPTB;NT60NVE5PCEQvF2=	M4W2fHNCVkeHUh?=
AGS	M2n6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrlRpVKSzVyPUWuOFk3OThizszN	NELHfHFUSU6JRWK=
SW13	NHPoXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPB[otKSzVyPUWuOVMzPjVizszN	MYDTRW5ITVJ?
SW1990	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rYVGlEPTB;NT62NlI5PSEQvF2=	NWD4WGZ{W0GQR1XS
BFTC-905	MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7TVIZKSzVyPUWuOlU5PzhizszN	MoqwV2FPT0WU
RMG-I	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjifVlKSzVyPUWuOlU6PDJizszN	NWHWWIF6W0GQR1XS
HD-MY-Z	M3XHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3H1NGlEPTB;NT62PFU5OSEQvF2=	MXnTRW5ITVJ?
HCC1187	M3\3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXO3SHpUUUN3ME21MlcyODN{IN88US=>	M{i0NHNCVkeHUh?=
HCC2998	NEL0WZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnToTWM2OD13LkexPFc4KM7:TR?=	NF7vd5RUSU6JRWK=
RT-112	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTVwOUCyOFUh\|ryP	NUDiNlNjW0GQR1XS
CAKI-1	NETFb\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zCTWlEPTB;Nj6wNFk5PSEQvF2=	NFrHN4FUSU6JRWK=
HDLM-2	NGD2bohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnwW4xKSzVyPU[uNFE1QDlizszN	MUDTRW5ITVJ?
TE-10	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;UXIZoUUN3ME22MlA1QDN\|IN88US=>	NWTxPXNZW0GQR1XS
KE-37	NWHZfIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvUTWM2OD14LkC3NlU5KM7:TR?=	MXTTRW5ITVJ?
RCM-1	NV3K[4l7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTZwMEe3NVkh\|ryP	M{frNnNCVkeHUh?=
Mewo	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTZwMUG0PFch\|ryP	NVrBTo1QW0GQR1XS
L-428	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTZwMUiwN\|ch\|ryP	NIrMboNUSU6JRWK=
8-MG-BA	NVz1V3c6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTZwMUmzO\|kh\|ryP	MV;TRW5ITVJ?
SK-MEL-28	M1vKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLvfZBOUUN3ME22MlIxQTZ5IN88US=>	NVX2TpNGW0GQR1XS
VA-ES-BJ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnWNmh3UUN3ME22MlMxPDZ{IN88US=>	NI\1OZNUSU6JRWK=
CAL-120	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofyTWM2OD14LkS1NVYzKM7:TR?=	MVXTRW5ITVJ?
GAMG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;peG1KSzVyPU[uOVA3OiEQvF2=	NVn0S2p[W0GQR1XS
MSTO-221H	M2K5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnPcHVFUUN3ME22MlUyOTdizszN	NYLqVnlMW0GQR1XS
GCT	NFPmRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETheGpKSzVyPU[uOVM{QDdizszN	NUP1bpRtW0GQR1XS
SH-4	M2T6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL1SoNPUUN3ME22MlU5QDR2IN88US=>	MlnIV2FPT0WU
Calu-3	NVLEbG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrOTWM2OD14Lk[1OVY5KM7:TR?=	NV3TWYN1W0GQR1XS
SK-HEP-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTqTWM2OD14LkexO\|U{KM7:TR?=	MlvNV2FPT0WU
PFSK-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1KzfWlEPTB;Nj63N\|Q4QCEQvF2=	NF;BUHFUSU6JRWK=
NB12	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTZwN{i0NFQh\|ryP	MXXTRW5ITVJ?
A388	NWj0SJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTZwOEm1NkDPxE1?	NGTmOGxUSU6JRWK=
KLE	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LGT2lEPTB;Nj65OlUyPiEQvF2=	MWrTRW5ITVJ?
TE-11	NHq1[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TGNGlEPTB;Nz6wOFk3PyEQvF2=	MVjTRW5ITVJ?
NCI-H2405	NYf6emtjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXztPHZHUUN3ME23MlA5Ozl\|IN88US=>	MWDTRW5ITVJ?
OVCAR-4	NF;IOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrjWmpKSzVyPUeuNVU{PSEQvF2=	M3HJbXNCVkeHUh?=
KP-N-YS	NF;kUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTdwMUixOEDPxE1?	M3HqTXNCVkeHUh?=
NOS-1	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XYXmlEPTB;Nz6yOVgzQCEQvF2=	MWXTRW5ITVJ?
DMS-114	NVLofWZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTdwMkm2N\|Eh\|ryP	M4ja[nNCVkeHUh?=
NCI-H2030	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDiTWM2OD15LkOzOlk5KM7:TR?=	M{TsR3NCVkeHUh?=
HEL	NUXuUnNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHHTWM2OD15LkO3OVIyKM7:TR?=	MVTTRW5ITVJ?
CAL-62	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkiyTWM2OD15LkO5PFY3KM7:TR?=	M1TEXXNCVkeHUh?=
COLO-668	NGPUdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPGTWM2OD15LkSzPVY4KM7:TR?=	NEKzUWVUSU6JRWK=
SKG-IIIa	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3wOW1TUUN3ME23MlQ2OzhzIN88US=>	MlTwV2FPT0WU
HCC1419	MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTdwNE[4N\|Mh\|ryP	NFX3eoFUSU6JRWK=
OS-RC-2	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXpXWVKSzVyPUeuOFk5QTRizszN	MVLTRW5ITVJ?
COLO-829	NFPJPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTdwNk[0OlMh\|ryP	NV;ESI9HW0GQR1XS
NB13	M3LGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTdwOEK2Olch\|ryP	NID4eW9USU6JRWK=
DK-MG	NXHzeXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3THTmlEPTB;Nz64N\|IxOSEQvF2=	NW\Ub5hlW0GQR1XS
SHP-77	M4nmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTdwOE[2OVMh\|ryP	MXvTRW5ITVJ?
NCI-H661	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRThwMEW4Olch\|ryP	M3O2SXNCVkeHUh?=
AM-38	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLrTWM2OD16LkG2Nlgh\|ryP	NYe2SGVZW0GQR1XS
VM-CUB-1	NUnFR4J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\tTWM2OD16LkG3NFI6KM7:TR?=	NUXxcGp[W0GQR1XS
KYSE-70	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2GzS2lEPTB;OD6xPVc3OSEQvF2=	MX\TRW5ITVJ?
5637	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHPTWM2OD16LkOxNFU2KM7:TR?=	MkXLV2FPT0WU
TGBC11TKB	NG\KcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPsTWM2OD16LkS2NVY1KM7:TR?=	Mm\OV2FPT0WU
EGI-1	NXjscHJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjHUGdKSzVyPUiuOlAxQDhizszN	NHrYNI1USU6JRWK=
D-392MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXqeHlKSzVyPUiuOlYzOTRizszN	NETEU4lUSU6JRWK=
A673	NWPxbmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRThwNke2NVEh\|ryP	M1PzeHNCVkeHUh?=
COLO-792	NYq3OpAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHmTWM2OD16Lke0PVQ3KM7:TR?=	NUO2U2cyW0GQR1XS
NCI-H1792	M3vaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX61WVd5UUN3ME24Mlg5QTB\|IN88US=>	NUDmOnp5W0GQR1XS
LS-1034	M1H1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTFTnlrUUN3ME24Mlk1PjV{IN88US=>	NFTGfWxUSU6JRWK=
D-566MG	NYHNS2NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTlwMEG4NUDPxE1?	M4LaRXNCVkeHUh?=
NCI-H226	M{m4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HyUWlEPTB;OT6wPUDPxE1?	NH\TWIZUSU6JRWK=
ChaGo-K-1	NGfXTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:5ZmtKSzVyPUmuNVA2PzlizszN	MV7TRW5ITVJ?
NCI-H2228	NVfo[VRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmewTWM2OD17LkGxNFgyKM7:TR?=	NED0NmZUSU6JRWK=
RPMI-8226	NVuzXldST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1f2ZmlEPTB;OT6xNVMxPCEQvF2=	NIPMXoRUSU6JRWK=
BFTC-909	NILrZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HjZ2lEPTB;OT6xPFI6PyEQvF2=	NVfheWVqW0GQR1XS
HPAF-II	NYe3R5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUP1O2oyUUN3ME25MlIzPTF6IN88US=>	NFHHW4hUSU6JRWK=
Capan-2	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnQTWM2OD17LkSwNVA6KM7:TR?=	MoXuV2FPT0WU
IA-LM	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDhTWM2OD17LkSxPVY3KM7:TR?=	NFfMRWtUSU6JRWK=
KP-4	M2rRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIe0U2NKSzVyPUmuOFg5OzhizszN	MVXTRW5ITVJ?
A101D	NELG[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2SyfGlEPTB;OT61NVcyQSEQvF2=	MX;TRW5ITVJ?
EFO-21	NHHu[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVH2bIZGUUN3ME25MlU5PzN3IN88US=>	M{n0OnNCVkeHUh?=
C32	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e4O2lEPTB;OT62N\|M1KM7:TR?=	MkPrV2FPT0WU
SW837	NFG4SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\tfmlEPTB;OT64OFgzKM7:TR?=	NYG4[HRIW0GQR1XS
OCI-AML2	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvRVXVwUUN3ME25Mlg3QTZizszN	NUHPeFRZW0GQR1XS
NCI-H1355	NELwd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfhTWM2OD17Lkm0NFg5KM7:TR?=	NFnBPVBUSU6JRWK=
NCI-H2342	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzWTWM2OD1zMD6wNVU2KM7:TR?=	NXvXVZNiW0GQR1XS
A204	M4LHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmH6TWM2OD1zMD6wOFY3KM7:TR?=	MmTaV2FPT0WU
CAL-51	M2fMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojtTWM2OD1zMD6wPFc4KM7:TR?=	MlSwV2FPT0WU
HCE-4	NXjaWlkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfCcG5KSzVyPUGwMlEyOjJizszN	NGDzeFRUSU6JRWK=
NCI-H810	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfWU5FTUUN3ME2xNE4yPTl5IN88US=>	Mn61V2FPT0WU
DJM-1	NGTYdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{X2VGlEPTB;MUCuNVc{OiEQvF2=	M4nWO3NCVkeHUh?=
SK-UT-1	NV3JU\|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFyLkK1O\|Qh\|ryP	NGSyRotUSU6JRWK=
U031	MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofXTWM2OD1zMD6yOlg3KM7:TR?=	NYDTbYg2W0GQR1XS
YH-13	NYXLXWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInKeIRKSzVyPUGwMlMxPTdizszN	NG\GOIFUSU6JRWK=
K5	NXXYTm1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFyLkOzPVUh\|ryP	NF3TdlZUSU6JRWK=
HEC-1	NEf4OW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7IOpV4UUN3ME2xNE41ODhzIN88US=>	NUTSNJF2W0GQR1XS
A2058	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\VTWM2OD1zMD61OFkyKM7:TR?=	NHXKenZUSU6JRWK=
SW962	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{i0e2lEPTB;MUCuOlIxPCEQvF2=	NYDsfYNVW0GQR1XS
VMRC-RCZ	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vyTGlEPTB;MUCuOlc1QSEQvF2=	M3;pbnNCVkeHUh?=
D-336MG	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rQ[2lEPTB;MUCuO\|AxPSEQvF2=	MV\TRW5ITVJ?
LXF-289	NWLORWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnTT49KSzVyPUGwMlc6PjdizszN	Ml3jV2FPT0WU
SW900	NUHyR4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvtNohKSzVyPUGwMlgzOjhizszN	NGL1UJFUSU6JRWK=
K-562	M17OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4mwfmlEPTB;MUCuPFM6PSEQvF2=	MVzTRW5ITVJ?
HCC38	NXzZdWdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTFyLkm3NVYh\|ryP	NWXhN\|J5W0GQR1XS
SF-295	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYS3R5pRUUN3ME2xNE46QTB{IN88US=>	NYGxUXd{W0GQR1XS
LB831-BLC	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVr4emRuUUN3ME2xNU4zPTV4IN88US=>	MoK2V2FPT0WU
FTC-133	NUHaOYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjLTWM2OD1zMT6zNFgyKM7:TR?=	MoPpV2FPT0WU
HCC1954	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHhTWM2OD1zMT60N\|Yh\|ryP	NFy3RZpUSU6JRWK=
GOTO	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFzLkWyNFYh\|ryP	M2PCZ3NCVkeHUh?=
LS-411N	NH23coRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37PV2lEPTB;MUGuOlExOSEQvF2=	NUexT3pFW0GQR1XS
RPMI-7951	M{ntOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYK2TJg1UUN3ME2xNU43OzR6IN88US=>	NX\wSpFiW0GQR1XS
NCI-H1299	M33xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFzLk[2OFch\|ryP	NIHUUYNUSU6JRWK=
MLMA	MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLnTWM2OD1zMT62PVk4KM7:TR?=	M{jYWHNCVkeHUh?=
MMAC-SF	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonpTWM2OD1zMT63NlUzKM7:TR?=	MVrTRW5ITVJ?
UM-UC-3	NYDqXXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHjOHJKSzVyPUGxMlc1OjFizszN	NF24UohUSU6JRWK=
SCC-9	NGXOXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFzLkixOVEh\|ryP	M3y4[XNCVkeHUh?=
HOS	NITaRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFzLki2PFMh\|ryP	NVHwc4VYW0GQR1XS
OE19	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zJOmlEPTB;MUGuPVM3PyEQvF2=	NWXDeVZYW0GQR1XS
Mo-T	NF\qboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfWO3BKSzVyPUGxMlk2PDFizszN	NWTmRmhPW0GQR1XS
CAMA-1	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfJTWM2OD1zMj6xOlM{KM7:TR?=	NVzqSI9ZW0GQR1XS
U-118-MG	NYjJT\|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorCTWM2OD1zMj6yOFQyKM7:TR?=	NHnET2lUSU6JRWK=
KS-1	M2rCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF{LkK4N\|Ih\|ryP	M3ezTnNCVkeHUh?=
JAR	M3OzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\DVmlEPTB;MUKuN\|M3QSEQvF2=	Mlq1V2FPT0WU
ABC-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzoSppGUUN3ME2xNk4{PDFizszN	NX65TnpDW0GQR1XS
Daoy	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrnZ2lKSzVyPUGyMlQ2PDJizszN	M33sT3NCVkeHUh?=
C3A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrRPIdKSzVyPUGyMlU4QDVizszN	MV3TRW5ITVJ?
GT3TKB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33aSmlEPTB;MUKuOlMzPyEQvF2=	MVLTRW5ITVJ?
DMS-273	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTF{Lki2N\|Mh\|ryP	M1TF[HNCVkeHUh?=
G-361	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3iOotHUUN3ME2xNk46OTJ7IN88US=>	MXXTRW5ITVJ?
RH-18	M1rMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTF\|LkK5OlIh\|ryP	MVrTRW5ITVJ?
SN12C	NHnl[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7K[ItJUUN3ME2xN{4{QDB6IN88US=>	NGX0bGZUSU6JRWK=
NCI-H1993	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTF\|LkSyPFUh\|ryP	NUDhTXR2W0GQR1XS
LOXIMVI	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHOx[ndKSzVyPUGzMlYyPTFizszN	NH;hTJJUSU6JRWK=
SK-PN-DW	NH7ocYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjHTVBKSzVyPUGzMlg1OjdizszN	NXnqTWttW0GQR1XS
KALS-1	NIXCb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL6[4VKSzVyPUGzMlg2OjVizszN	MnrkV2FPT0WU
LAN-6	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTF2LkK1N{DPxE1?	M3;1OnNCVkeHUh?=
A549	NV7aV\|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfme2JKSzVyPUG0MlQ4OTJizszN	NWXocnZwW0GQR1XS
RD	NVPE[ZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPrTWM2OD1zND60PFE{KM7:TR?=	Mn21V2FPT0WU
TGBC1TKB	NY\oO\|JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF2Lk[2NVUh\|ryP	NV;STI1QW0GQR1XS
NCI-H630	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LoV2lEPTB;MUSuPVQ3PyEQvF2=	NYnn[oFDW0GQR1XS
MIA-PaCa-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HuUGlEPTB;MUSuPVY6KM7:TR?=	MUDTRW5ITVJ?
NCI-H1755	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fqWGlEPTB;MUSuPVk2OyEQvF2=	NFjDT2ZUSU6JRWK=
MOLT-4	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnxUXhCUUN3ME2xOU4xPDl5IN88US=>	MmmzV2FPT0WU
CW-2	NGCzc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;qWmlEPTB;MUWuNVQzOSEQvF2=	MVnTRW5ITVJ?
COLO-320-HSR	NUPnOZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;5RWlEPTB;MUWuOVMxPyEQvF2=	MV7TRW5ITVJ?
UMC-11	M1fWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\rbIdKSzVyPUG1Mlc2OjNizszN	NVPBdnJWW0GQR1XS
MCF7	M{mxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W1NGlEPTB;MUWuPFE1PSEQvF2=	MojFV2FPT0WU
NCI-H23	NE\MS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTF3Lki0N\|gh\|ryP	Ml3RV2FPT0WU
HuCCT1	NY\uSHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF3Lki3OEDPxE1?	M1nkTXNCVkeHUh?=
MPP-89	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF3Lkm0NVch\|ryP	NH7P[JZUSU6JRWK=
HT55	NX\0Z2xuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofCTWM2OD1zNT65OFc5KM7:TR?=	M1jOVXNCVkeHUh?=
no-11	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEW5cphKSzVyPUG1Mlk3PjNizszN	MlLWV2FPT0WU
GP5d	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF4LkKxPFch\|ryP	M2HoVHNCVkeHUh?=
BHT-101	NUOzTmp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTF4LkK0N\|kh\|ryP	NX7LWJhOW0GQR1XS
M059J	NG\RZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvVTWM2OD1zNj6yPFQh\|ryP	NUPTZnVjW0GQR1XS
D-283MED	M3:3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2L6bmlEPTB;MU[uOFIxQSEQvF2=	MoTDV2FPT0WU
BEN	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTF4LkWxOVUh\|ryP	NFXUe21USU6JRWK=
LB373-MEL-D	NED3U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVztVVc1UUN3ME2xOk44OjN{IN88US=>	NFzHN2FUSU6JRWK=
MEL-HO	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X5VWlEPTB;MU[uPFg2PCEQvF2=	NIXnXFdUSU6JRWK=
GI-ME-N	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4mzcmlEPTB;MU[uPVA{OiEQvF2=	M2\pT3NCVkeHUh?=
RKO	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTF5LkC3OFgh\|ryP	MlfDV2FPT0WU
MZ2-MEL	M3XYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fNd2lEPTB;MUeuNVM{KM7:TR?=	MkDUV2FPT0WU
NCI-H1573	M3X5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TKdmlEPTB;MUeuNlgzPiEQvF2=	NXv4NFdkW0GQR1XS
NCI-H1581	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTF5LkS0NVEh\|ryP	MoPTV2FPT0WU
NCI-H747	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDhTWM2OD1zNz61Nlk4KM7:TR?=	M{C4VHNCVkeHUh?=
SW1783	M3;5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkX3TWM2OD1zNz62OFE2KM7:TR?=	Ml7zV2FPT0WU
Calu-6	NInvV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTF5Lk[3PFIh\|ryP	MofvV2FPT0WU
SF268	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\qcGlEPTB;MUeuOlk3QSEQvF2=	MkC3V2FPT0WU
ES8	NFP5dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3mwUGlEPTB;MUeuPFU6OyEQvF2=	MV\TRW5ITVJ?
KM-H2	NFvyV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LlUmlEPTB;MUeuPVQyOSEQvF2=	M2jRdXNCVkeHUh?=
D-502MG	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTF5Lkm4NFgh\|ryP	M3rhcHNCVkeHUh?=
HLE	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnz4TWM2OD1zOD6zNVQ5KM7:TR?=	M3Ow[nNCVkeHUh?=
SW982	M{PWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITJTnNKSzVyPUG4MlQxPzVizszN	MYTTRW5ITVJ?
MDA-MB-361	NVHCbJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTF6LkW1PFgh\|ryP	M1ftdHNCVkeHUh?=
NCI-H1563	Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XwXmlEPTB;MUiuO\|EzPCEQvF2=	NIOxOIlUSU6JRWK=
MFE-280	NWXadZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDlTWM2OD1zOD63Nlk{KM7:TR?=	M17LWHNCVkeHUh?=
U251	NXnsdo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2H3fmlEPTB;MUiuO\|M1PyEQvF2=	MX3TRW5ITVJ?
KNS-42	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLVTWM2OD1zOD64NFE2KM7:TR?=	NV7uVlZDW0GQR1XS
U-266	NIr4b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXXVFJ1UUN3ME2xPE45PjR7IN88US=>	MnXzV2FPT0WU
OVCAR-8	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3jcJhKSzVyPUG4MlkzPzZizszN	M1KwXnNCVkeHUh?=
MFH-ino	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHRTWM2OD1zOD65OlY6KM7:TR?=	NX7aVVNKW0GQR1XS
D-263MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn[wTWM2OD1zOT6wNVczKM7:TR?=	NELI[W9USU6JRWK=
NCI-H1437	M{nIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTF7LkC0Olch\|ryP	MX7TRW5ITVJ?
NCI-H1048	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3RbopKSzVyPUG5MlI{OjZizszN	M4i2RnNCVkeHUh?=
NCI-H446	NWGzVo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF7LkO1PFkh\|ryP	MYnTRW5ITVJ?
NCI-N87	MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XhWGlEPTB;MUmuOVk6OiEQvF2=	NFPpPYdUSU6JRWK=
WM-115	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF7Lk[3O\|Qh\|ryP	NYTWcFZuW0GQR1XS
HuH-7	NWfBUHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jJO2lEPTB;MUmuO\|QzOSEQvF2=	MVjTRW5ITVJ?
NCI-H650	NETRXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF7Lke1NFgh\|ryP	MULTRW5ITVJ?
TYK-nu	NFj4cpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnnS3hKSzVyPUG5Mlg{PzhizszN	NYq4dZNRW0GQR1XS
Becker	NUPLdIMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC2TWM2OD1zOT64OVQ4KM7:TR?=	MkTKV2FPT0WU
BB49-HNC	M4XkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFr6N4lKSzVyPUG5MlkzKM7:TR?=	NYnlb3pHW0GQR1XS
HGC-27	NEm3TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP6TWM2OD1{MD6xN\|k1KM7:TR?=	MlnyV2FPT0WU
SiHa	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XGZWlEPTB;MkCuN\|cyOiEQvF2=	Mly1V2FPT0WU
LB2518-MEL	NYq1S25CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXBb2M6UUN3ME2yNE4{PzN7IN88US=>	MUjTRW5ITVJ?
TE-5	M4qzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\2TWM2OD1{MD63OFgzKM7:TR?=	M3G4OHNCVkeHUh?=
IST-SL1	M2PhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJyLke4O\|kh\|ryP	NHn2bodUSU6JRWK=
A375	NIDudIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrmVJBKSzVyPUKxMlA2PjdizszN	NIX0fWRUSU6JRWK=
MC116	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\QTWM2OD1{MT6wO\|I{KM7:TR?=	NWLJbFNyW0GQR1XS
GI-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2G3[mlEPTB;MkGuNVch\|ryP	MWDTRW5ITVJ?
HOP-62	M2rsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\R[GlEPTB;MkGuNlc5PCEQvF2=	MXzTRW5ITVJ?
PA-1	NEGzbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnRN\|dKSzVyPUKxMlI4QDdizszN	MUHTRW5ITVJ?
HT	NFTQfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;iRmo{UUN3ME2yNU41OzNzIN88US=>	M4i0XnNCVkeHUh?=
HUTU-80	M{XWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\FelBzUUN3ME2yNU41OzN4IN88US=>	MmnYV2FPT0WU
NCI-H1975	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHX4Z2FKSzVyPUKxMlQ3OSEQvF2=	NIjtS2RUSU6JRWK=
GAK	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTJzLkS5PUDPxE1?	M2LVUnNCVkeHUh?=
SK-N-AS	NILacFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fQZ2lEPTB;MkGuOVYyQSEQvF2=	M{XVc3NCVkeHUh?=
OE33	M4rH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJzLk[wOFYh\|ryP	MWfTRW5ITVJ?
YKG-1	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;rTWM2OD1{MT62OVQ2KM7:TR?=	NHPCNXpUSU6JRWK=
CAL-85	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf6RWtiUUN3ME2yNU46OzB3IN88US=>	MYDTRW5ITVJ?
NCI-H2347	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmG1TWM2OD1{MT65OFI5KM7:TR?=	NF3weG1USU6JRWK=
PANC-08-13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILnUYZKSzVyPUKyMlAyOTlizszN	Mki0V2FPT0WU
SK-N-FI	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI[2PFhKSzVyPUKyMlMxPzRizszN	MXnTRW5ITVJ?
NEC8	M1P1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHQTWM2OD1{Mj61NFc5KM7:TR?=	NXj3TnZ1W0GQR1XS
AN3-CA	M4q2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m3NGlEPTB;MkKuOlA5PCEQvF2=	M{H0OXNCVkeHUh?=
HuO9	MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFS3VZlKSzVyPUKyMlc{QTZizszN	NVfGVVRtW0GQR1XS
COLO-800	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILLVFFKSzVyPUKyMlc3PTNizszN	MkT4V2FPT0WU
HT-29	NGHFXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXCOFB3UUN3ME2yNk45QDJ\|IN88US=>	M4PxSHNCVkeHUh?=
OC-314	NGG2VVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDTdIpCUUN3ME2yNk45QDR3IN88US=>	MVTTRW5ITVJ?
G-401	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjsbnZKSzVyPUKzMlA1PjJizszN	MWPTRW5ITVJ?
Saos-2	M3fBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlniTWM2OD1{Mz61NVgzKM7:TR?=	NFvyc4pUSU6JRWK=
UACC-62	NGXocYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfpTWM2OD1{Mz61PFM{KM7:TR?=	NGDpWlhUSU6JRWK=
D-247MG	NHLqTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJ\|Lke5N\|kh\|ryP	M1z0dXNCVkeHUh?=
COLO-741	M1f5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr6VZdKSzVyPUKzMlk2PjVizszN	NUnQNIFLW0GQR1XS
ES3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrjTWM2OD1{ND6wNFI{KM7:TR?=	MlTtV2FPT0WU
LNCaP-Clone-FGC	NID5elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkf6TWM2OD1{ND6wNlEyKM7:TR?=	MUDTRW5ITVJ?
SW1710	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;0UmtLUUN3ME2yOE4yPTB4IN88US=>	NIjhfZBUSU6JRWK=
LU-99A	NGrtPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\IdmlEPTB;MkSuNVg1OSEQvF2=	M33aeXNCVkeHUh?=
HOP-92	M3fjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjFTWM2OD1{ND63NlUh\|ryP	NVOyTJN3W0GQR1XS
LS-123	NVL0V45XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\O[pl2UUN3ME2yOE46PjF2IN88US=>	MnH1V2FPT0WU
T84	M3LPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJ2Lkm3OlUh\|ryP	NXjid5BJW0GQR1XS
HCT-116	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfmRo5KSzVyPUK1MlQyQDZizszN	NYe1UlNDW0GQR1XS
M14	MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr6bGlKSzVyPUK1MlQ1PDdizszN	NEX4[mFUSU6JRWK=
OCUB-M	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkn3TWM2OD1{NT60OFU3KM7:TR?=	NWSzPIdpW0GQR1XS
MKN45	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTJ3Lk[zNVUh\|ryP	NVLKbW43W0GQR1XS
LCLC-97TM1	NHTCTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHmeWRKSzVyPUK1MlczQDVizszN	MX\TRW5ITVJ?
RVH-421	NULPdGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDOTWM2OD1{NT64NVYyKM7:TR?=	MlfYV2FPT0WU
NKS-81-FD	NEe4fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDRdHN6UUN3ME2yOU46ODJzIN88US=>	NFLlWWFUSU6JRWK=
NCI-H596	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJ4LkC0PFch\|ryP	NETGWGtUSU6JRWK=
GB-1	NInhSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIP1cHNKSzVyPUK2MlE5PzlizszN	MWfTRW5ITVJ?
ZR-75-30	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJ4LkKyPVch\|ryP	NHHnfYZUSU6JRWK=
U-2-OS	NFv5OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\qdZBnUUN3ME2yOk4{PzV5IN88US=>	MnzDV2FPT0WU
HuP-T3	M3O3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\LTWM2OD1{Nj62NVAzKM7:TR?=	NVPFNXVVW0GQR1XS
MOLT-16	NX;xZldoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz1[IRKSzVyPUK2MlYyPjZizszN	NIfNWHZUSU6JRWK=
U-87-MG	NWPCXWltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO1TWM2OD1{Nj63OFM5KM7:TR?=	MkfpV2FPT0WU
8505C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXVTWM2OD1{Nj65NVI3KM7:TR?=	Ml3qV2FPT0WU
SK-MEL-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n3RWlEPTB;Mk[uPVgzQCEQvF2=	MXrTRW5ITVJ?
COLO-824	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWm4enhQUUN3ME2yO{4zOTl3IN88US=>	MVPTRW5ITVJ?
EW-1	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f3SmlEPTB;MkeuN\|U2PCEQvF2=	MWTTRW5ITVJ?
UACC-257	M2POcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXMTWM2OD1{Nz6zPFA1KM7:TR?=	NHrqUXFUSU6JRWK=
Hs-578-T	M17Dcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTJ5LkWyPVkh\|ryP	M2PyU3NCVkeHUh?=
UACC-893	NFe1bG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLJ[IE1UUN3ME2yO{43PjNzIN88US=>	M4fhNHNCVkeHUh?=
MHH-NB-11	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\1bmlEPTB;MkeuPFAxPyEQvF2=	MYfTRW5ITVJ?
KYSE-410	M4Phb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGK4WXdKSzVyPUK4MlI4PzlizszN	M2K3PHNCVkeHUh?=
SF126	M1;HeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTqXYRKSzVyPUK4Mlc1OzVizszN	MYPTRW5ITVJ?
HT-144	NF3WW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2e2XmlEPTB;MkmuN\|M3OiEQvF2=	NE\vVVdUSU6JRWK=
SW1573	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr0Wm1{UUN3ME2yPU4{PTB7IN88US=>	MX\TRW5ITVJ?
SW620	NILKU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJ7LkO2OFEh\|ryP	MlW0V2FPT0WU
SCH	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJ7Lki4N\|Eh\|ryP	MoPBV2FPT0WU
EW-22	M{K5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTwd4ZTUUN3ME2zNE4yQTZ7IN88US=>	M1LHPXNCVkeHUh?=
H4	NYGzN5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTNyLkS2OVQh\|ryP	M4fqbnNCVkeHUh?=
CAS-1	NXPVOFJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjHVVlKSzVyPUOwMlc5PTlizszN	NETM[IJUSU6JRWK=
MG-63	M1OyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGS5UpVKSzVyPUOwMlg1PzhizszN	M{XNS3NCVkeHUh?=
MDA-MB-415	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonKTWM2OD1\|MT6xO\|U{KM7:TR?=	MUnTRW5ITVJ?
NCI-H1395	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfRXY5KSzVyPUOxMlI{OjhizszN	NH7ETVlUSU6JRWK=
Ca-Ski	NFHNZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTNzLkOxO\|ch\|ryP	NULyRmNMW0GQR1XS
BxPC-3	NXzVfZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zpcGlEPTB;M{GuN\|czQSEQvF2=	Ml7FV2FPT0WU
A3-KAW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTNzLkS0O\|Eh\|ryP	MXrTRW5ITVJ?
T-24	M2\H[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTNzLkezOlIh\|ryP	NEDFRY5USU6JRWK=
NCI-H2029	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrQTWM2OD1\|MT63O\|Y2KM7:TR?=	Mn3hV2FPT0WU
YAPC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LyTmlEPTB;M{KuNFQxPyEQvF2=	MYrTRW5ITVJ?
SK-MEL-2	M4XnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTN{LkC1NkDPxE1?	M3TOOXNCVkeHUh?=
LS-513	NV3YbpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1iwW2lEPTB;M{KuNVE5PyEQvF2=	MnuyV2FPT0WU
AsPC-1	NU\TTWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7FWWV{UUN3ME2zNk4{PjB3IN88US=>	Mmj1V2FPT0WU
KYSE-150	MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nYNmlEPTB;M{KuN\|c4OyEQvF2=	M1;pcXNCVkeHUh?=
NCI-H520	M1nK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPa[WVKSzVyPUOyMlQ1QDJizszN	NX[4c2pJW0GQR1XS
JEG-3	NW\4cYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkO0TWM2OD1\|Mz6wPVcyKM7:TR?=	NF70T5JUSU6JRWK=
GMS-10	M1TZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3RS41KSzVyPUOzMlMxODRizszN	MVrTRW5ITVJ?
HT-1080	M1r4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPFdopKSzVyPUOzMlM6KM7:TR?=	M{H5XnNCVkeHUh?=
NCI-H1651	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHWTWM2OD1\|Mz6zPVYh\|ryP	NUXSdo84W0GQR1XS
NCI-H2122	NHTHd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPUSJhQUUN3ME2zN{42PTd2IN88US=>	NF3Yb\|RUSU6JRWK=
ES5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTN\|LkeyPVIh\|ryP	MXTTRW5ITVJ?
8305C	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTN\|Lkm5N\|ch\|ryP	MkPQV2FPT0WU
KM12	NWXrXpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjrbIJKSzVyPUO0MlA1PzhizszN	M4[5RXNCVkeHUh?=
HCT-15	M1rle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W1PWlEPTB;M{SuNVI4KM7:TR?=	NUTuPVZUW0GQR1XS
OVCAR-5	M{XzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEmwVlRKSzVyPUO0MlIyQDJizszN	M1rPVXNCVkeHUh?=
NCI-H2291	MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXFeJBKSzVyPUO0MlI1PzJizszN	NXHpPIpzW0GQR1XS
CP50-MEL-B	NFjpbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjsfHM{UUN3ME2zOE43PTl{IN88US=>	M{\HfHNCVkeHUh?=
C-33-A	M2m4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j6TGlEPTB;M{SuOlg2PyEQvF2=	M4\qWHNCVkeHUh?=
NCI-H2452	M3HKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkOyTWM2OD1\|ND63PFgzKM7:TR?=	Ml3zV2FPT0WU
MDA-MB-157	M1rLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXoU3BKSzVyPUO0MlgyQTNizszN	NH\OSIdUSU6JRWK=
LN-405	NGDpU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4L6dGlEPTB;M{WuOFMxQCEQvF2=	M{DpcnNCVkeHUh?=
MDA-MB-231	M2LZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TyUmlEPTB;M{WuOVA2PCEQvF2=	NILLb5pUSU6JRWK=
EW-24	M3z4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXRTWM2OD1\|NT62N\|M2KM7:TR?=	MlzxV2FPT0WU
MKN28	M4\jNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTN3LkiyN\|Yh\|ryP	MXzTRW5ITVJ?
KINGS-1	NYrRd3h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF32NJlKSzVyPUO1Mlg1OzRizszN	M{nEcnNCVkeHUh?=
LC-2-ad	MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTN4Lk[5PUDPxE1?	M3nQeHNCVkeHUh?=
IGR-1	NXHyO3p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLlTWM2OD1\|Nj63NFc2KM7:TR?=	NVrpZmdkW0GQR1XS
SW626	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPSTWM2OD1\|Nz6wOFE4KM7:TR?=	MkXIV2FPT0WU
ONS-76	NYi2Wm9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\p[3R[UUN3ME2zO{4yOzB7IN88US=>	MoDiV2FPT0WU
T98G	M3n3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3YTWM2OD1\|Nz64OlM2KM7:TR?=	NHnSRmZUSU6JRWK=
NB14	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTN6LkS1OFQh\|ryP	NVfDbGRGW0GQR1XS
D-423MG	NFrLbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLhUot2UUN3ME2zPE41QDZ7IN88US=>	NEDVfmpUSU6JRWK=
NCI-H510A	NY\RfYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTN6Lk[0OVEh\|ryP	NYriNVVNW0GQR1XS
NMC-G1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETqeFJKSzVyPUO4MlczOjJizszN	MkDlV2FPT0WU
SW948	M{XEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTydItlUUN3ME2zPE45QTR7IN88US=>	M2K1OHNCVkeHUh?=
MFM-223	M3jrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT6[ndKSzVyPUO4Mlk1OzFizszN	Mn[1V2FPT0WU
PAN1	NVfYW3plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXGbo5KSzVyPUO4Mlk6OTlizszN	MY\TRW5ITVJ?
MZ7-mel	M2O0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYq2eJg1UUN3ME2zPU4yOTl7IN88US=>	NFm4RWJUSU6JRWK=
COLO-679	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;pbWlEPTB;M{muPVcxQCEQvF2=	M3TFV3NCVkeHUh?=
SW872	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLqZ\|BrUUN3ME20NE4zODNzIN88US=>	MmfvV2FPT0WU
HT-1197	NELtSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTaW2tJUUN3ME20NE4zQDZ7IN88US=>	MYjTRW5ITVJ?
ES6	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfwenJKSzVyPUSwMlQ2PTJizszN	Mn[0V2FPT0WU
SNU-387	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfoTWM2OD12MD64NlM5KM7:TR?=	M1np[XNCVkeHUh?=
T47D	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK1[2dnUUN3ME20NU4xOTl{IN88US=>	MXzTRW5ITVJ?
G-402	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVi2NXpIUUN3ME20NU4xQDB7IN88US=>	NG\6ZlBUSU6JRWK=
MZ1-PC	M3TncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfnPJRKSzVyPUSxMlgyKM7:TR?=	NWHNS\|JHW0GQR1XS
SW1417	NHfWU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Pn[2lEPTB;NEKuN\|A{KM7:TR?=	MXTTRW5ITVJ?
RERF-LC-MS	NW[3UItrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fZWmlEPTB;NEKuOVA5PyEQvF2=	NFjJSYtUSU6JRWK=
SF539	NF:4Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PUZWlEPTB;NEKuOVUzQSEQvF2=	M1G2[3NCVkeHUh?=
ESS-1	M4fpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3CTWM2OD12Mz61OVU5KM7:TR?=	NFXEdYJUSU6JRWK=
RO82-W-1	NHizSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTR\|Lk[xOVMh\|ryP	NHjKWYtUSU6JRWK=
S-117	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDwN45KSzVyPUSzMlY6PThizszN	NYHJZVA4W0GQR1XS
SW756	NEHJR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTR\|LkiyOFIh\|ryP	MX;TRW5ITVJ?
CP66-MEL	M3ziU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7mZm5KSzVyPUS1MlcyPDNizszN	NF3rS2NUSU6JRWK=
H-EMC-SS	NED3[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fCW2lEPTB;NEWuO\|Y6OyEQvF2=	MlnNV2FPT0WU
NCI-H2052	M2[1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3n0VmlEPTB;NEWuPVAzPyEQvF2=	NHe4SHVUSU6JRWK=
SW684	NHTafYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlj6TWM2OD12Nz6wNFgyKM7:TR?=	MXrTRW5ITVJ?
HCC1569	NHnKb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4CyWWlEPTB;NEeuNVY2QCEQvF2=	NE[2[ndUSU6JRWK=
KGN	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\UWWtDUUN3ME20O{4{OzFzIN88US=>	M2DOcHNCVkeHUh?=
LCLC-103H	NFPaSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jQ[2lEPTB;NEeuOFQxPCEQvF2=	M4HRTnNCVkeHUh?=
SW780	M4D2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvVR25KSzVyPUS3MlY{PTFizszN	NUTtbVNSW0GQR1XS
NCI-H1703	M2e4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTnbJIyUUN3ME20PE4{OzV{IN88US=>	MVXTRW5ITVJ?
HCC1395	NITsWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHu[WpKSzVyPUS4Mlc1OzJizszN	MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Iressa
Smiles	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)